A LTHOUGH THE USE OF PSYCHOACTIVE substances by motor vehicle drivers is suspected as a major risk factor in traffi c, valid information on psychoactive substance use by motorists is sparse (Behrensdorff and Steentoft, 2003 ; European Monitoring Centre for Drugs and Drug Addiction, 2008) . Prevalence studies are, in general, complex and expensive to conduct, partly because of the relatively low incidence of psychoactive substances in traffi c. For a study to have enough statistical power, many drivers need to be included.
Review studies report a large variation of drivers in general traffi c positive for one or more psychoactive substances other than alcohol. It is diffi cult to directly compare the results of these roadside surveys because of differences in study design, such as the number of substances included, the analytical cutoff levels applied, and the biological matrix used (European Monitoring Centre for Drugs and Drug Addiction, 2008; Kelly et al., 2004; Walsh et al., 2004) . In Norway, 4.5% of motor vehicle drivers were positive for psychoactive substances including illicit drugs, medicinal drugs, or alcohol (Gjerde et al., 2008) . In Thailand, 5.5% of drivers tested positive for alcohol, and 9.7% of drivers were positive for other psychoactive substances (Ingsathit et al., 2009 ). In the state of Victoria, Australia, 2.4% of drivers were positive for methamphetamines, 3,4-methylenedioxymethamphetamine (MDMA, or Ecstasy), or tetrahydrocannabinol (THC, or cannabis). In the United States, 11% of drivers were positive for illicit and medicinal drugs during daytime hours on Friday and 14.4% during nighttime hours on Friday and Saturday nights (Lacey et al., 2009) . In British Columbia, 10.4% of drivers tested positive for drug use on Wednesday and Saturday nights.
In the European research project DRUID (Driving Under the Infl uence of Drugs, Alcohol and Medicines), prevalence studies have been conducted from 2007 to 2009 in 13 European countries (Houwing et al., 2011a (Houwing et al., , 2011b . Special attention was given to the comparability of these studies by using a common study design (Assum et al., 2007) , which included recommendations on the type of road users and substances to be included, as well as the cutoff levels of these substances. Despite recommendations for a common design, some differences could not be ruled out for practical, legislative, or medical ethical reasons. The main difference in the design of these 13 studies was that some countries used blood as the biological matrix, some used oral fl uid, and some used a combination of both. To be able to compare the results from countries that used blood with countries that used oral fl uid, equivalent cutoffs were applied, as reported by Verstraete et al. (2011b) and Gjerde et al. (2010) . When using equivalent cutoff concentrations in blood and oral fl uid, the prevalence of a drug will be equal in samples of blood and samples of oral fl uid when studying a large cohort. Based on the outcomes of these 13 studies and after application of weighing factors for country size and size of the represented European regions, it was estimated that an average of 1.89% of the drivers in the European Union were positive for illicit drugs, 1.39% for medicinal drugs, 3.48% for alcohol, 0.39% for polydrug use, and 0.37% for the combined use of alcohol and other drugs (Houwing et al., 2011a) .
Belgium and The Netherlands are two neighboring countries in Western Europe that shared a common history until 1830, when Belgium separated from The Netherlands. Comparisons between Belgium and The Netherlands are commonly made because of their historical and cultural bonds. A comparison of Dutch and Belgian results is also interesting because they were the only two Western European countries that were involved in the DRUID roadside surveys. This article reports on and compares the use of psychoactive substances in traffi c based on results of the Belgian and Dutch prevalence studies that were conducted in the European DRUID project. Furthermore, Dutch and Belgian results are compared with the estimated European mean and with previously conducted national studies in Belgium and The Netherlands on the use of psychoactive substances in traffi c.
Method

General design
A cross-sectional roadside survey was conducted to determine the prevalence of psychoactive substances among the general driving population in Belgium and The Netherlands. A stratifi ed multistage sampling design was used. In the fi rst stage, fi ve study regions were selected in Belgium and The Netherlands. These regions were meant to be representative of the entire country with regard to substance use and traffi c. Within these regions, smaller research areas (fi ve Belgian and six Dutch police regions) were selected in the second stage. Within these areas, survey locations were selected in which car drivers and van drivers were randomly selected from actual traffi c between January 2007 and August 2009. For each police region, data were collected during several roadside survey sessions distributed over eight 6-hour periods covering all hours of the day on both weekdays and weekend days. The periods were distributed into type of day (weekday/ weekend day) and time of day (4:00 A.M.-9:59 A.M., 10:00 A.M.-3:59 P.M., 4 P.M.-9:59 P.M., and 10 P.M.-3:59 A.M.).
Drivers were stopped by the police at the request of the research coordinator. As soon as an interviewer/nurse was ready for interviewing and blood sampling, a driver (i.e., the next car approaching the research site) was stopped. Drivers who were stopped were asked to cooperate with the study on a voluntary basis. Drivers who agreed to cooperate were interviewed about their drug and medicine use. Apart from self-reported drug use and time of administration, data collection also comprised date and time of selection, gender and age of the subject, and signs of impairment. In Belgium, all drivers were asked to provide both blood and oral fl uid samples. If drivers refused to give a blood sample, a single oral fl uid sample was requested. In the Belgian study, participating drivers received a reward of €20. In the Dutch study, all drivers were asked to give a blood sample. If drivers refused to give a blood sample, an oral fl uid sample was requested. Participants received a €5 reward for an oral fl uid sample and a €10 reward for a blood sample. In case drivers reported recent drug use, an additional oral fl uid sample was requested after collecting a blood sample.
In The Netherlands as well as in Belgium, the breath test was compulsory for all drivers who were stopped. In The Netherlands, participants were breath tested for alcohol by a police offi cer after the interview and the blood or oral fl uid sampling. Drivers who refused to participate were breath tested for alcohol by a police offi cer, and, if possible, additional information was collected including information on age, gender, clinical signs of impairment, and reason for refusal. In Belgium, all drivers who were stopped were breath tested before the request regarding participation in the study.
Ethical approval
In Belgium, the protocol was approved by the ethics committee of Ghent University Hospital. Participants needed to sign an informed consent. No ethical approval was needed in The Netherlands. After having been informed about the project, the ethics committee made clear that "the project is not encompassed by the law on ethics committees and consideration regarding bio-medical research projects. Therefore, the project does not have to be announced to the ethics committee." Hence, no informed consent was requested. However, participants in The Netherlands were informed both in writing and by oral communication about the study and its voluntary nature.
Sample preparation and analysis
Venous blood samples were collected in glass tubes containing 20 mg sodium fl uoride and 143 IU heparin sodium (BD Plymouth, Brest, The Netherlands, and Terumo, Leuven, Belgium) . In The Netherlands, oral fl uid samples were taken by having the participant spit into a polypropylene container (Deltalab, Barcelona, Spain) . In Belgium, oral fl uid samples were collected by using the StatSure Saliva Sampler (StatSure Diagnositc Systems, Inc., Brooklyn, MA). In The Netherlands, estimated blood alcohol concentration (BAC) was measured with a handheld breath alcohol analyzer using a Dräger Alcotest 7410 Plus screening device (Dräeger Safety Inc., Lübeck, Germany). In Belgium, BAC was estimated from both oral fl uid and whole blood. For drivers from whom only oral fl uid samples were collected, results for ethanol (alcohol) in oral fl uid were converted using the following formula:
Calculated blood ethanol (%) = measured ethanol in oral fl uid (g/L) × 1.22.
The applied factor of 1.22 was based on the average conversion factor between blood and oral fl uid that was calculated from the Belgian DRUID results of those drivers from whom both blood and oral fl uid samples were collected (Verstraete et al., unpublished observations) . In Belgium, the following methods were used for toxicological analysis of whole blood samples: an enzymatic method for ethanol analysis, a solid-phase extraction followed by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis for all substances except cannabinoids, enzyme-linked immunosorbent assay (ELISA) screening (qualitative) for cannabinoids, and liquid-liquid extraction followed by gas chromatography-mass spectrometry analysis for samples that gave positive results at the ELISA screening for cannabinoids.
An enzymatic method for ethanol analysis and protein precipitation, followed by UPLC-MS/MS for all other substances, was used for the Dutch toxicological analysis of whole blood samples. Four rounds of profi ciency testing were organized in the participating countries during the study.
In The Netherlands, the conversion factor of breath alcohol concentrations into BACs in percentages is 1:23 (Mathijssen and Twisk, 2001 ). However, in other European countries that were involved in the DRUID roadside surveys, a higher conversion factor of 1:21 is used (Melethil, 2011) . To be able to compare the Dutch alcohol results with the results for other European Union countries, all BAC results from The Netherlands were multiplied by a factor of 1.095 (23 / 21).
Equivalent cutoffs
In total, 23 substances were included in the analysis. Selection of these substances was based on their prevalence of use in the general population and their possible infl uence on driving ability. Results were presented by using equivalent cutoffs. When using equivalent cutoff concentrations in blood and oral fl uid, the prevalence of a drug will be equal in samples of blood and samples of oral fl uid when studying a large cohort. The reason for applying equivalent cutoffs is that, for many substances, concentrations in oral fl uid are much higher than in blood, whereas for some compounds the concentrations are lower (Verstraete et al., 2011b) . Table  1 provides an overview of the applied cutoff concentrations. In case both blood and oral fl uid samples were available, the result from the blood analysis was leading.
Substance groups and classes`
For calculating prevalence, substances of the same type were aggregated into substance groups. All groups were mutually exclusive, meaning that each record was either negative or linked to one of the following groups: alcohol, amphetamines, cocaine, THC, illicit opiates, benzodiazepines, Z drugs (nonbenzodiazepine medications mainly used for the treatment of insomnia), and medicinal opioids. Samples in which only THC-COOH (11-nor-9-carboxy-THC; a metabolite of THC that is detectable in blood and that occurs in very Notes: TCH-COOH = 11-nor-9-carboxy-tetrahydrocannabinol; MDA = methylenedioxyamphetamine; MDEA = 3,4-methylenedioxy-N-ethylamphetamine; MDMA = 3,4-methylenedioxymethamphetamine; THC = tetrahydrocannabinol.
low concentrations in oral fl uid) was detected were regarded as negative. Samples that included substances from two or more substance groups were included either in the drugdrug combination group or in the alcohol-drug combination group, depending on the presence of alcohol. More detailed information on the aggregation into substance groups and classes can be found in Houwing et al. (2011a) . Morphine and codeine concentrations could be classifi ed as medicinal opioids or as illicit opiates. Morphine and codeine were regarded, in general, as medicinal opioids, except in those cases when they were detected in combination with each other and when the concentration of morphine was higher than the concentration of codeine. A higher concentration of morphine would suggest the use of an illicit opiate such as heroin.
Weighing factors
Because random sampling was applied, drivers were expected to be representative of gender and age during sampling sessions. However, because police preferences had to be considered, the selection of samples could not be distributed equally with traffi c volumes over the different periods. To correct for the difference between distribution of roadside samples and distribution of traffi c over eight different periods, weight factors were calculated by dividing the general distribution of traffi c by period by the distribution of sampled drivers in the same period. 
Statistical analysis
Weighted prevalence was calculated by using descriptive statistics by means of the statistical software SAS Version 9.2 (SAS Institute, Cary, NC). Tables were created by using a FREQ procedure including a statement on the weight factors to be used. Weighted prevalence of the substance under scrutiny was calculated by dividing the weighted number of positives for this substance by the weighted total of samples. For calculating confi dence intervals, the Wilson confi dence interval formula (Wilson, 1927) was used because lower and upper confi dence limits calculated using traditional approximations may result in limits outside the (0,1) interval. Possible differences in substance use between the two countries were investigated with binomial logistic regression in SPSS Version 16.0.1 (SPSS Inc., Chicago, IL). Type of country was used as a covariate (with two categories: 0 = Belgium, 1 = The Netherlands), and each substance was included as a dependent variable (also with two categories: 0 = negative, 1 = positive). In all statistical tests, the conventional critical 5% level was used to assess whether the obtained odds ratio (OR) signifi cantly deviated from 1.
Results
Study population
In The Netherlands, 5,064 drivers were asked to participate in this study. Of these drivers, 242 (4.8%) declined and 4,822 (95.2%) agreed to participate. In Belgium, 6,155 drivers were asked to participate. Of these drivers, 3,206 (52.1%) refused and 2,949 (47.9%) agreed to participate. Of the 4,822 participating drivers in the Dutch study, 3,476 (72%) provided a blood sample, 1,068 (22%) provided an oral fl uid sample, and 278 (6%) provided both a blood and an oral fl uid sample. As stated previously, in case both blood and oral fl uid samples were collected, the results of the blood analysis were leading. In the Belgian study, 2,750 (93%) of the 2,949 participating drivers provided both blood and oral fl uid samples, and 199 (7%) provided an oral fl uid sample only. Table 2 provides an overview of the distribution of the participating drivers by age and gender. No information on age was available from 5 drivers in The Netherlands and 21 drivers in Belgium.
There was no signifi cant difference in the age and gender distribution between the two survey samples. Distribution (Houwing et al., 2011b) showed that there was a small but signifi cant overrepresentation of male drivers among the nonresponse group. This overrepresentation was mainly present in the 25-to 34-year-old age group. The prevalence of illicit drugs was generally higher among young male drivers (Houwing et al., 2011a (Houwing et al., , 2011b . Furthermore, it was shown that from 4:00 A.M. to 9:59 A.M. on both weekday/weekend days and from 10:00 A.M. to 3:59 P.M. on weekends, the refusal rates were highest. Alcohol prevalence among respondents did not differ with the prevalence found in nonrespondents (p = .321).
The nonresponse rate in The Netherlands was only 4.8%. The prevalence of alcohol was slightly higher for the nonresponse group than for the response group. However, the BAC distribution of the combined response and nonresponse group was almost identical to the BAC distribution of the response group alone. The self-reported use of psychoactive substances other than alcohol was higher for the nonresponse group. After correction for the unknown answers, 6.5% of the nonrespondents reported the use of psychoactive substances in the past 12 hours versus 3.6% of the respondents. When the self-reported use of the nonresponse group would have been added, the self-reported use of the total study population would increase just one tenth of a percentage point, from 3.6% to 3.7%. Table 3 provides a general overview of the prevalence of psychoactive substances in Dutch and Belgian traffi c. As mentioned above, the substance groups were divided into four drug categories: alcohol, illicit drugs, medicinal drugs, and combined use of drugs or drugs with alcohol.
Prevalence
Alcohol. In both countries, single alcohol use (BAC > .01%) was the most prevalent substance. The prevalence of single alcohol use in Belgian traffi c (6.42%) was signifi cantly higher (OR = 3.15, 95% CI [2.46, 4.03]) than in Dutch traffi c (2.15%) (Figure 1 ). For each of the three BAC groups, the prevalence in Belgium was at least twice as high as in The Netherlands. However, the relative difference decreased at higher BAC levels. Alcohol was used in combination with other psychoactive substances far less frequently than alone. In The Netherlands, the prevalence of alcohol in combination with other psychoactive substances was 0.24%, which was 10% of the total prevalence of alcohol. In Belgium, the prevalence of alcohol in combination with other substances was 0.31%, which was 5% of the total prevalence of alcohol.
Illicit drugs. The illicit drug class consisted of four different illicit drug groups: amphetamines, cocaine, cannabis, and illicit opiates (Table 1) . In The Netherlands, 2.17% of all drivers were positive for illicit drugs, whereas in Belgium the prevalence was lower, at only 0.64%, a signifi cant difference (OR = 0.27, 95% CI [0.16, 0.45]). THC was by far the most frequently detected illicit drug in The Netherlands (1.67%) and in Belgium (0.35%). The THC prevalence in Belgium was signifi cantly lower than in The Netherlands (OR = 0.21, 95% CI [0.11, 0.40] the absence of amphetamines in the Belgian study sample, a value of 0.1 was added to each of the four cells (Agresti, 1996) , which resulted in a nonsignifi cant difference (OR = 0.02, 95% CI [0. 00, 8.97] ) between the Dutch and Belgian prevalence. Illicit opiates were rarely present (0.01%) in The Netherlands and sparsely detected in Belgium (0.09%). This difference was not signifi cant either (OR = 11.11, 95% CI [0.29, 432.54] ).
Medicinal drugs. The medicinal drugs class consisted of three different drug groups: benzodiazepines, medicinal opioids, and Z drugs (see Table 1 ). Medicinal drugs were signifi cantly more prevalent in general traffi c in Belgium (2.98%) than in The Netherlands (0.60%) (OR = 6.40, 95% CI [4.00, 10.25]). The most frequently detected medicinal drugs were benzodiazepines. In The Netherlands, 0.40% of the drivers were screened positive for benzodiazepines, as did 2.01% in Belgium (OR = 5.16, 95% CI [3.08, 8 .66]) (Figure 1 ). Medicinal opioids were detected relatively frequently in Belgium (0.75%) but signifi cantly less in The Netherlands (0.16%) (OR = 4.60, 95% CI [2.04, 10.37]). Z drugs were signifi cantly more prevalent in Belgium (0.22%) than in The Netherlands (0.04%) (OR = 5.12, 95% CI [1.08,
24.31]).
Drug-drug and alcohol-drug combinations. Patterns of the prevalence of combinations of psychoactive substances were more or less the same in The Netherlands (0.24% alcohol-drugs and 0.35% drug-drug combinations) and in Belgium (0.31% alcohol-drugs and 0.30% drug-drug combinations). The corresponding odds ratios were not signifi cant (alcohol-drugs, OR = 1.37, 95% CI [0.62, 3.00]; drug-drug combinations, OR = 0.76, 95% CI [0.34, 1.71]). Both in Belgium and in The Netherlands, cocaine was detected with approximately the same frequency alone as it was in combination with other substances. For THC, Z drugs, and medicinal opiates and opioids, the share of combined use was approximately 25% of the total use, whereas for alcohol and benzodiazepines the proportion was about 10% in both countries. For amphetamines (0.00% in Belgium) and illicit opiates (0.01% in The Netherlands), the prevalence was too low to compare between countries.
Comparison with previous studies in The Netherlands and Belgium
In The Netherlands, only one previous prevalence study had been conducted in the past 10 years on the prevalence of drugs and medicines in traffi c (Mathijssen and Houwing, 2005) . For alcohol prevalence, data were available on a yearly basis since 1974, but this information was only gath-FIGURE 1. Prevalence of substances alone and in combination; prevalence in percentages. Combi = combination; BE = Belgium; NL = The Netherlands; ETH = ethanol (alcohol); AMP = amphetamines; COC = cocaine; THC = tetrahydrocannabinol (cannabis); OPI = illicit opiates; BDZ = benzodiazepines; ZDR = Z drugs; MOPI = medicinal opioids. ered during weekend nights (Dienst Verkeer en Scheepvaart, 2011). For the prevalence of alcohol during other periods, only data from the European research project IMMORTAL (Impaired Motorists, Methods of Roadside Testing and Assessment for Licensing) were available (Mathijssen and Houwing, 2005) .
Between 2000 and 2004, a roadside survey was conducted in the Dutch Tilburg police district as part of the European IMMORTAL study. The prevalence of single illicit drugs was higher in the IMMORTAL study (4.5%) than it was in the Dutch DRUID study (2.17%). However, the results of the IMMORTAL study were mainly based on urine samples in which drugs are detectable for a longer period than in blood and oral fl uid (Verstraete, 2004) . Therefore, a direct comparison between the prevalence rates of the IMMORTAL and DRUID studies was not possible.
In Belgium, national data on the prevalence of alcohol in traffi c were available for the years 2003 , 2005 (DuPont, 2009 . No previous data were available on the prevalence of other psychoactive substances in traffi c. The prevalence of alcohol in the DRUID study was somewhat higher than the results from the biannual roadside survey on alcohol use, which found an average prevalence of 2% during the whole week for a BAC of 0.5 g/L and higher. In the DRUID study, this prevalence was 2.33%. These results did not signifi cantly differ from each other.
Comparison with DRUID mean
Within the DRUID project, a European mean was estimated based on the prevalence of psychoactive substances in 13 different European countries including The Netherlands and Belgium using a uniform study design . Figure 2 presents the comparison of the Dutch and Belgian prevalence data (including 95% confi dence intervals) with the estimated European mean.
The results show that the relative position of the Belgian and Dutch results toward the European mean was mirrored for all substances. Benzodiazepines, medicinal opiates and opioids, and alcohol were more frequently detected in Belgium as opposed to the European mean, whereas in The Netherlands they were less frequently detected than in Europe. However, the prevalence of amphetamines and THC in Dutch traffi c was above the European average, and the prevalence of these substances in Belgium was below average. The prevalence of cocaine, illicit opiates, Z drugs, alcohol-drugs, and drug-drug combinations in traffi c varied between the two countries; but, for all of these substances, the European mean was included in the confi dence interval for both countries.
Discussion
Despite the fact that Belgium and The Netherlands are neighboring countries, the use of psychoactive substances in traffi c was far from similar. In Belgium, the use of alcohol and medicinal drugs in traffi c was higher than in The Netherlands, whereas the measured use of illicit substances in traffi c was substantially higher in The Netherlands as compared with Belgium.
The higher prevalence for alcohol in Belgium might be related to differences in the enforcement level. The enforcement level for alcohol (number of alcohol tests per 100,000 inhabitants) is estimated to be three to four times lower in Belgium than it is in The Netherlands (Veisten et al., 2011) . Furthermore, cultural differences may be causing higher alcohol use in Belgian traffi c. For example, in Belgium, people tend to go out eating and drinking more often. This is refl ected in the number of restaurants per 10,000 inhabitants. In The Netherlands, the number of restaurants per 10,000 inhabitants is approximately 35 (Bedrijfschap Horeca en Catering, 2011), whereas in the Flanders region-where about 60% of all Belgian inhabitants reside-the number of restaurants per 10,000 inhabitants is approximately 48 (GUIDEA, 2011) .
The higher use of medicinal drugs in Belgium might be explained by a higher consumption of medicines in the general population. The average expenditure per person on medicines has been approximately 15%-20% higher in Belgium than in The Netherlands (Stichting Farmaceutische Kergetallen, 2011) . The low expenditure in The Netherlands could partly be explained by a reluctant prescription policy of general practitioners.
The relatively low prevalence of illicit drugs that was found in Belgium may be related to the high nonresponse level. It can be expected that drivers who had recently used an illicit drug would be less likely to participate in the study because they might be afraid that the test results would be used for legal purposes (drug driving legislation of 1999). A lower participation rate of drug-positive drivers would result in nonresponse bias. Based on a comparison of the detected prevalence of illicit substances among injured drivers (Isalberti et al., 2011) and in the general population (Ravera and De Gier, 2008) , a higher prevalence of illicit drugs in Belgian traffi c would indeed be expected. The detected prevalence of illicit drugs in the general population was in fact comparable for the two countries, and the detected prevalence of illicit drugs among injured drivers was even higher for Belgium than it was for The Netherlands.
Another indication of nonresponse bias can be derived from the odds ratios for illicit drugs that were calculated by Hels et al. (2011) . Because of the low prevalence of illicit drugs in Belgium, only an adjusted odds ratio for getting seriously injured in a car crash could be calculated for cannabis. The Belgian odds ratio for cannabis (4.88) was approximately three times higher than the mean adjusted odds ratio (1.38) in Hels et al. (2011) , which was based on the combined data of four included countries (Belgium, Denmark, The Netherlands, and Lithuania). If the mean adjusted odds ratio would be applied to the Belgian hospital data, the estimated prevalence for THC in Belgian traffi c is likely to be more comparable to the Dutch prevalence, although it is impossible to estimate the exact size of the potential nonresponse bias. Finally, keep in mind that, in this study, prevalence is based on predetermined limits of detection and not on limits of impairment.
Strengths and limitations
The main strength of the present study is the similar design of roadside surveys performed in both Belgium and The Netherlands, which makes it possible to compare the results between the two countries as well as with the estimated European mean. By using equivalent cutoffs for drugs in blood and oral fl uid, the limitation of the comparability of the results when including two different body fl uid samples (blood and oral fl uid) was overcome. Another strength of this study is that blood and oral fl uid samples were used, not urine samples. Blood and oral fl uid can be used to detect recent drug use, whereas urine samples may refl ect drug intake up to several days ago (Verstraete, 2004; Walsh et al., 2008) . Furthermore, the study provides recent prevalence data of different psychoactive substances in the general driving population in Belgium and The Netherlands. For Belgium, this is the fi rst large-scale study that includes information on the prevalence of illicit drugs in traffi c.
A limitation of this study is that the list of analyzed substances was not exhaustive. For example, there was no screening for gamma-hydroxybutyric acid (GHB), only seven benzodiazepines were screened for, and selective serotonin reuptake inhibitors were not included. The very high nonresponse rate (52.1%) in Belgium is another limitation of the study because it could lead to nonresponse bias, especially for illicit drugs. Based on the assessment on possible confounding effects of nonresponse by comparing age, gender, and alcohol data, we can conclude that the possibility of nonresponse bias cannot be totally ruled out. Despite that there was a signifi cant difference (p < .001) in self-reported use of psychoactive substances other than alcohol between the response and the nonresponse group in The Netherlands, the actual bias seems to be very small because of the small size of the nonresponse group.
Another limitation is that the studies in Belgium and The Netherlands did not collect oral fl uid in the same way. The collection procedure may have infl uenced the concentrations of the samples, as described in previous literature (Crouch, 2005; Langel et al., 2008; O'Neal et al., 2000; Verstraete et al., 2011a) . Furthermore, a recent study (Houwing et al. , submitted for publication) shows that THC concentrations in oral fl uid samples collected by spit tubes were on average 1.9 times higher than THC concentrations collected by the StatSure collection device. These fi ndings indicate that the applied equivalent cutoff concentrations might have been too high for the Dutch study.
Finally, despite the large sample size of the Belgian and Dutch prevalence study, the cell counts for some substances were small or even zero, which resulted in less stable comparisons between the estimates of both countries.
Conclusion
The Netherlands and Belgium are neighboring countries. Nonetheless, statistical signifi cant differences are present in the prevalence of psychoactive substances in traffi c. In general, medicinal drug use and alcohol were more frequently detected in Belgian traffi c, whereas illicit substances were more prevalent in The Netherlands. However, when comparing the results of roadside surveys with hospital data and data from illicit drug use in the general population, it is likely that the observed prevalence of illicit drugs at the Belgian roadside was underrepresented and that the prevalence of illicit drugs in Belgian traffi c is probably higher than the current results show.
